ALNY (alnylam.com) Earnings per share growth this year

Official company branding of Alnylam Corp (ALNY)

Alnylam Pharmaceuticals (ALNY) dominates the orphan drug segment, leveraging its monopoly position to establish high pricing power. The percentage deviation of EPS from last year's level visualizes the market reaction, where 693.20 captures the current state of the parameter. Growth is driven by the expansion of RNA therapy into cardiology and infectious diseases, while the development strategy relies on proprietary research and global licensing alliances.

ALNY (alnylam.com) Earnings per share growth in current year history from 07/04/2022 to 11/17/2026

Financial and market metric breakdowns for alnylam.com (ALNY)

- stock value and consensus price forecast:
Basic company analysis:Alnylam Corp (ALNY)
Manufactured products of Alnylam Pharmaceuticals

Alnylam Pharmaceuticals (ALNY) maintains its status as the primary innovator in RNA therapeutics, providing the brand with exceptional credibility within the medical community. By analyzing the relative EPS growth over 12 months, an investor assesses the dynamics of net profit per share compared to the previous year, where stabilizing volatility signals business maturity and confirms the fundamental resilience of the company's market positions.

Main competitors

Earnings per share growth rate in current year Vertex Pharmaceuticals Inc. (VRTX)|INSM (Insmed) - Earnings growth in current year|Earnings per share growth this year UTHR (United Therapeutics Corporation)|Net earnings per share growth this year BMRN (BioMarin)|BBIO (BridgeBio Pharma) - Earnings per share increase in current year|Earnings growth in current year BGM (BGM Group Ltd)|COGT (Cogent Bio) - Earnings per share trend in current year|Xeris Biopharma - Earnings growth in current year|Earnings per share increase in current year KROS (Keros Therapeutics)|ARCT: Earnings growth in current year|Eton Pharmaceuticals Inc (ETON) - Earnings growth in current year|Earnings per share growth in current year Kamada Corp|FULC: Earnings per share increase in current year|Earnings per share growth in current year Abeona Therapeutics, Inc. (ABEO)|Net earnings per share growth this year Mereo BioPharma Group plc MREO|Earnings per share growth in current year Protalix BioTherapeutics PLX|Earnings growth in current year Pliant Therapeutics PLRX|appliedtherapeutics.com - Earnings growth in current year|Earnings per share increase in current year RNTX (Rein Therapeutics, Inc.)|GELS: Earnings growth in current year|Earnings per share growth rate in current year Aytu BioPharma, Inc. (AYTU)|CMMB (Chemomab Therapeutics Ltd) - Earnings growth in current year|Earnings per share growth this year SRXH (SRx Health Solutions)|Net earnings per share growth this year PLRZ (Polyrizon Ltd)|AEZS - Earnings per share growth rate in current year|Earnings per share growth in current year Cyclo Therapeutics Inc. CYTH|Inozyme Pharma, Inc. (INZY) - Earnings per share growth rate in current year|RPHM: Net earnings per share growth this year|Earnings per share growth rate in current year COSCIENS Biopharma Inc